Tg Therapeutics (TGTX) Change in Receivables (2021 - 2026)

Tg Therapeutics' Change in Receivables history runs 6 years deep, the most recent figure standing at $86.4 million for Q1 2026.

• On a quarterly basis, Change in Receivables rose 41.82% year-over-year to $86.4 million in Q1 2026; TTM through Mar 2026 was $201.9 million, a 61.36% increase from a year earlier, with the FY2025 full-year figure at $176.4 million, up 125.94% from the prior year.
• Change in Receivables grew to $86.4 million in Q1 2026 per TGTX's latest filing, from $40.2 million in the prior quarter.
• Across five years, Change in Receivables topped out at $86.4 million in Q1 2026 and bottomed at -$814000.0 in Q2 2022.
• The 5-year median for Change in Receivables is $16.3 million (2024), against an average of $24.4 million.
• Across the five-year window, Change in Receivables tumbled 608.75% in 2022 and surged 24913.64% in 2023, its largest moves.
• Year by year, Change in Receivables stood at -$88000.0 in 2022, then surged by 13478.41% to $11.8 million in 2023, then climbed by 14.31% to $13.5 million in 2024, then soared by 199.03% to $40.2 million in 2025, then jumped by 114.74% to $86.4 million in 2026.
• Per Business Quant, the three latest TGTX Change in Receivables figures stand at $86.4 million (Q1 2026), $40.2 million (Q4 2025), and $33.9 million (Q3 2025).